Beneficio del tercer trimestre de AstraZeneca supera las estimaciones debido al crecimiento de las ventas de medicamentos contra el cáncer

Resumen del corpus

AstraZeneca reported third-quarter earnings that surpassed expectations, driven by robust sales growth in its oncology drugs. Core earnings per share reached $2.79, marking a 19% increase, exceeding the estimated $2.62. This strong performance was primarily fueled by the expansion within its oncology business segment.